Growing Prevalence Of Neurodegenerative Disorders Fuels Neurodegenerative Disorder Therapeutics Market: Pivotal Factor Influencing Neurodegenerative Disorder Therapeutics Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Neurodegenerative Disorder Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market size for therapeutics for neurodegenerative disorders has seen robust growth. The growth is expected to rise from $18.53 billion in 2024 to $20.04 billion in 2025, maintaining a compound annual growth rate (CAGR) of 8.1%. Factors such as an aging population, an increased occurrence of neurodegenerative disorders, a rise in life expectancy, an upsurge in investment from pharmaceutical companies, and heightened awareness and advocacy have all contributed to this growth during the historical period.

How Will the Neurodegenerative Disorder Therapeutics Market Size Evolve and Grow by 2029?
In the upcoming years, the market for therapeutics in neurodegenerative disorders is anticipated to experience substantial growth. The market is projected to escalate to $28.33 billion in 2029 with a 9.0% compound annual growth rate (CAGR). The growth during the forecast period can be ascribed to factors such as the increasing demand for personalized and targeted therapies, the rise in the number of clinical trials, and an uptick in healthcare expenditure. Key trends observed during the forecast period are disease-modifying treatments, non-pharmacological interventions, the use of telemedicine and remote monitoring, technological advancements, precision therapeutics, digital health methodologies, and biomarker-led trials.

View the full report here:
https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

What Drivers Are Propelling the Growth of Neurodegenerative Disorder Therapeutics Market Forward?
The escalating instances of neurodegenerative disorders worldwide are fueling the expansion of the neurodegenerative disorder therapeutics market. This surge can largely be attributed to the rising numbers of the elderly, who are more susceptible to such conditions. For example, data from the World Population Prospects in 2024 shows that the population of individuals over 60 will expand to 2.1 billion by 2050. Moreover, the cohort aged 80 and over is anticipated to triple, reaching 425 million in 2050. The Alzheimer's Association reports that approximately 5.8 million Americans are currently living with Alzheimer's disease, a number that is expected to soar to close to 14 million by 2050. This amplified occurrence of neurodegenerative disorders among the senior population substantially drives the demand for therapeutics. Consequently, it bolsters the growth of the neurodegenerative disorder therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

Which Emerging Trends Are Transforming the Neurodegenerative Disorder Therapeutics Market in 2025?
Neurodegenerative disorder therapeutic manufacturers are coming together with both government and non-government bodies in a bid to research and create treatments for various neurodegenerative diseases. Additionally, these companies are collaborating more and more with their market counterparts to enhance their research and development prowess, with the aim of creating new and superior therapeutic solutions for neurodegenerative disorders. For example, NRG Therapeutics, a UK-based company focused on therapeutic approaches, established a partnership with Domainex, another UK-based drug discovery service, in July 2022. Their collective goal is to create pioneering small-molecule medications that can alter the course of disabling chronic neurodegenerative diseases such as Parkinson's disease and motor neuron disease (MND).

What Are the Key Segments in the Neurodegenerative Disorder Therapeutics Market?
The neurodegenerative disorder therapeutics market covered in this report is segmented -

1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Parkinson's Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer's Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington's Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp

Who Are the Key Players Shaping the Neurodegenerative Disorder Therapeutics Market's Competitive Landscape?
Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

What Geographic Markets Are Powering Growth in the Neurodegenerative Disorder Therapeutics Market?
The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2818

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.